Format

Send to

Choose Destination
Transl Androl Urol. 2017 Apr;6(2):326-330. doi: 10.21037/tau.2017.03.06.

Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer.

Ghiam AF1,2, Vesprini D1,2, Liu SK1,2,3.

Author information

1
Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Canada.
2
Department of Radiation Oncology, University of Toronto, Toronto, Canada.
3
Department of Medical Biophysics, University of Toronto, Toronto, Canada.

Abstract

Long non-coding RNAs (lncRNAs) are a group of non-coding transcripts of more than 200 nucleotides that play important biological and clinical roles in prostate cancer (PCa) tumorigenesis, progression and metastasis. They have also shown potential as a biomarker in the diagnosis and prognosis of this disease. LncRNA prostate cancer associated transcript-14 (PCAT-14) was recently identified as a novel prognostic biomarker in PCa, whose low expression was associated with poor outcomes. Here, we briefly discuss future perspectives and clinical applications of lncRNAs as biomarkers and therapeutic targets for PCa.

KEYWORDS:

Long non-coding RNA (lncRNA); biomarker; prostate cancer (PCa); radiotherapy (RT)

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center